MSA Trial Tracker
Browse active clinical trials for Multiple System Atrophy (MSA).
Tracker extracts data from ClinicalTrials.gov, a database managed by the National Library of Medicine (NLM) at the National Institutes of Health (NIH) in Bethesda, Maryland. This trial tracker is provided for informational purposes only and does not constitute medical or legal advice. Please consult with your healthcare provider for all diagnosis questions or medical treatment before taking any action or making any decision regarding your health.
Understanding Clinical Trial Phases & Status (click to show/hide)
Phase 1: A phase of research to describe clinical trials that focus on the safety of a drug. They are usually conducted with healthy volunteers, and the goal is to determine the drug's most frequent and serious adverse events and, often, how the drug is broken down and excreted by the body. These trials usually involve a small number of participants.
Phase 2: A phase of research to describe clinical trials that gather preliminary data on whether a drug works in people who have a certain condition/disease (that is, the drug's effectiveness). For example, participants receiving the drug may be compared to similar participants receiving a different treatment, usually an inactive substance (called a placebo) or a different drug. Safety continues to be evaluated, and short-term adverse events are studied.
Phase 3: A phase of research to describe clinical trials that gather more information about a drug's safety and effectiveness by studying different populations and different dosages and by using the drug in combination with other drugs. These studies typically involve more participants.
Phase 4: A phase of research to describe clinical trials occurring after the FDA has approved a drug for marketing. They include postmarket requirement and commitment studies that are required of or agreed to by the study sponsor. These trials gather additional information about a drug's safety, efficacy, or optimal use.
Phase Not Applicable: Describes trials without FDA-defined phases, including trials of devices or behavioral interventions.
Understanding the Status of active studies:
Not yet recruiting: The study has not started recruiting participants.
Recruiting: The study is currently recruiting participants.
Active, not recruiting: The study is ongoing, and participants are receiving an intervention or being examined, but potential participants are not currently being recruited or enrolled.
Filters
| Study ID | Title | Phase | Status | Start Date | Completion |
|---|---|---|---|---|---|
| NCT05696717 | Ampreloxetine | Phase Three | Active | Jun 2023 | Jan 2028 |
| NCT06706622 | Lu AF82422 | Phase Three | Active | Dec 2024 | Oct 2029 |
| NCT05923866 | ONO-2808 | Phase Two | Active | Sep 2023 | Jan 2027 |
| NCT06568237 | TEV-56286 | Phase Two | Active Recruiting | Oct 2024 | Sep 2027 |
| NCT06671938 | Safety, Tolerability, and Pharmacokinetics of Exidavnemab in Patients With MSA | Phase Two | Active | Oct 2024 | Aug 2026 |
| NCT06848231 | A Phase 2 Study of YA-101 in Patients With Multiple System Atrophy | Phase Two | Active Recruiting | Mar 2025 | Dec 2026 |
| NCT07197866 | An Extension Trial to Test if TEV-56286 is Effective in Relieving Multiple Syst… | Phase Two | Active Recruiting | Sep 2025 | May 2029 |
| NCT03482297 | Abdominal Binder | Phase One | Active Recruiting | Mar 2018 | Dec 2024 |
| NCT04165486 | ION464 | Phase One | Active Recruiting | Jul 2022 | Sep 2027 |
| NCT04680065 | GDNF Gene Therapy | Phase One | Active | Oct 2023 | Aug 2028 |
| NCT07446894 | Phase III Trial of MSA-01 in Multiple System Atrophy | Phase Three | Active Recruiting | Feb 2026 | Mar 2028 |
| NCT05104476 | A Study of Lu AF82422 in Participants With Multiple System Atrophy | Phase Two | Active | Nov 2021 | Mar 2028 |
| NCT05167721 | Stem cells | Phase Two | Active | Dec 2021 | Dec 2026 |
| NCT06120049 | PET vs SPECT (Single-Photon Emission Computed Tomography) | Phase Two | Active Recruiting | Jan 2024 | Jul 2026 |
| NCT06162013 | NAD Replenishment Therapy | Phase Two | Active Recruiting | Mar 2024 | Dec 2028 |
| NCT06868628 | A Phase 2a Study of Foralumab Nasal in Patients With Multiple System Atrophy (M… | Phase Two | Active Recruiting | May 2025 | Apr 2027 |
| NCT07465198 | Autologous Stem Cell Therapy in Patients With Multiple System Atrophy | Phase Two | Active Not Yet Recruiting | Sep 2026 | Mar 2031 |
| NCT02897063 | Midodrine and Droxidopa | Phase One | Active Recruiting | Sep 2016 | Dec 2026 |
| NCT04620382 | Midodrine vs Abdominal Compression | Phase One | Active Recruiting | Nov 2020 | Dec 2025 |
| NCT05698017 | Study to Evaluate Investigational Allogeneic Cell Therapy Product hOMSC300 for … | Phase One | Active | Nov 2022 | Feb 2026 |
| NCT06098612 | PET (Positron Emission Tomography) | Phase One | Active Recruiting | May 2024 | Nov 2027 |
| NCT06671236 | Regulatory T Cells (NP001 Cell Injection) | Phase One | Active Recruiting | Nov 2024 | Dec 2027 |
| NCT06683365 | Sural Nerve Grafting | Phase One | Active Recruiting | Feb 2025 | Dec 2030 |
| NCT06891703 | [18F]ACI-15916 PET in α-synucleinopathies | Phase One | Active Recruiting | Mar 2025 | Mar 2026 |
| NCT06765733 | The Study of Safety and Preliminary Efficacy of Aleeto in Patients with MSA | Phase One | Active Recruiting | May 2025 | Dec 2026 |
| NCT06607900 | hUC-MSC-sEV-001 Nasal Drops for Neurodegenerative Diseases | Phase One | Active Not Yet Recruiting | Jul 2025 | Aug 2028 |
| NCT06831500 | Feasibility of Carbidopa/Levodopa Ratio on Orthostatic Hypotension in MSA | Phase One | Active Recruiting | Jul 2025 | Nov 2026 |
| NCT07289477 | A Phase I/III Clinical Study to Evaluate NouvNeu001 Injection for Multiple Syst… | Phase One | Active Recruiting | Jan 2026 | Jul 2031 |
| NCT07476352 | Expansion Study of ALT001 in Patients With Multiple System Atrophy | Phase One | Active Not Yet Recruiting | May 2026 | Oct 2027 |
NCT06568237
TEV-56286
NCT06671938
Safety, Tolerability, and Pharmacokinetics of Exidavnemab in Patients With MSA
NCT06848231
A Phase 2 Study of YA-101 in Patients With Multiple System Atrophy
NCT07197866
An Extension Trial to Test if TEV-56286 is Effective in Relieving Multiple System Atrophy
NCT03482297
Abdominal Binder
NCT04165486
ION464
NCT04680065
GDNF Gene Therapy
NCT07446894
Phase III Trial of MSA-01 in Multiple System Atrophy
NCT05104476
A Study of Lu AF82422 in Participants With Multiple System Atrophy
NCT06120049
PET vs SPECT (Single-Photon Emission Computed Tomography)
NCT06162013
NAD Replenishment Therapy
NCT06868628
A Phase 2a Study of Foralumab Nasal in Patients With Multiple System Atrophy (MSA)
NCT07465198
Autologous Stem Cell Therapy in Patients With Multiple System Atrophy
NCT02897063
Midodrine and Droxidopa
NCT04620382
Midodrine vs Abdominal Compression
NCT05698017
Study to Evaluate Investigational Allogeneic Cell Therapy Product hOMSC300 for Treatment of Early t…
NCT06098612
PET (Positron Emission Tomography)
NCT06671236
Regulatory T Cells (NP001 Cell Injection)
NCT06683365
Sural Nerve Grafting
NCT06891703
[18F]ACI-15916 PET in α-synucleinopathies
NCT06765733
The Study of Safety and Preliminary Efficacy of Aleeto in Patients with MSA
NCT06607900
hUC-MSC-sEV-001 Nasal Drops for Neurodegenerative Diseases
NCT06831500
Feasibility of Carbidopa/Levodopa Ratio on Orthostatic Hypotension in MSA
NCT07289477
A Phase I/III Clinical Study to Evaluate NouvNeu001 Injection for Multiple System Atrophy
NCT07476352
Expansion Study of ALT001 in Patients With Multiple System Atrophy
Tracker extracts data from ClinicalTrials.gov, a database managed by the National Library of Medicine (NLM) at the National Institutes of Health (NIH) in Bethesda, Maryland. This trial tracker is provided for informational purposes only and does not constitute medical or legal advice. Please consult with your healthcare provider for all diagnosis questions or medical treatment before taking any action or making any decision regarding your health.
Understanding Clinical Trial Phases:
Phase 1: A phase of research to describe clinical trials that focus on the safety of a drug. They are usually conducted with healthy volunteers, and the goal is to determine the drug's most frequent and serious adverse events and, often, how the drug is broken down and excreted by the body. These trials usually involve a small number of participants.
Phase 2: A phase of research to describe clinical trials that gather preliminary data on whether a drug works in people who have a certain condition/disease (that is, the drug's effectiveness). For example, participants receiving the drug may be compared to similar participants receiving a different treatment, usually an inactive substance (called a placebo) or a different drug. Safety continues to be evaluated, and short-term adverse events are studied.
Phase 3: A phase of research to describe clinical trials that gather more information about a drug's safety and effectiveness by studying different populations and different dosages and by using the drug in combination with other drugs. These studies typically involve more participants.
Phase 4: A phase of research to describe clinical trials occurring after the FDA has approved a drug for marketing. They include postmarket requirement and commitment studies that are required of or agreed to by the study sponsor. These trials gather additional information about a drug's safety, efficacy, or optimal use.
Phase Not Applicable: Describes trials without FDA-defined phases, including trials of devices or behavioral interventions.
Understanding the Status of active studies:
Not yet recruiting: The study has not started recruiting participants.
Recruiting: The study is currently recruiting participants.
Active, not recruiting: The study is ongoing, and participants are receiving an intervention or being examined, but potential participants are not currently being recruited or enrolled.